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Background. Insulin-like growth factor I (IGF-I), a potent
proximal tubule cell (PTC) mitogen, has been implicated in
the progression of many human cancers. Our previous work on
human renal tissues has suggested that IGF-I and several of its
binding proteins (IGFBP-3 and -6) are up-regulated in clear cell
renal cell carcinoma (RCC).
Methods. To further elucidate the role of IGF-I and IGFBPs
in RCC growth, immunohistochemistry, thymidine incorpora-
tion, and Western analysis were performed in primary cultures
of normal PTC (priPTC) and clear-cell RCC (priRCC), as well
as in SN12K1 cells (a cell line derived from metastatic RCC).
Results. By immunohistochemistry, IGFBP-3 and IGF-I were
prominently expressed in SN12K1 cells, and weakly expressed
in priPTC and priRCC. Incubation with 100 ng/mL IGF-I sig-
nificantly augmented DNA synthesis by priPTC (mean ± SD
120.7% ± 19.7% of controls, P < 0.05), priRCC (238.7% ±
279.9% of controls, P < 0.01), and SN12K1(120.0% ± 22.9%
of controls, P < 0.05). Neutralizing antibodies to IGF-I and
IGF-I receptor significantly suppressed SN12K1 growth (81.9%
± 13.5% of control, P < 0.01 and 87.4% ± 16.2% of control,
P < 0.05, respectively). Removal of endogenous IGFBP-3 by
an anti-IGFBP-3 increased SN12K1 DNA synthesis (243.9%
± 35.3% of control, P < 0.001), which was partially abrogated
by coincubation with exogenous IGFBP-3 (135.97% ± 5.9% of
controls, P < 0.001). Using Western analysis, IGFBP-3 expres-
sion was enhanced in IGF-I–stimulated SN12K1 cells exposed
to exogenous IGF-I. Coincubation with anti-IGFBP-3 further
enhanced IGF-I–induced DNA synthesis.
Conclusion. RCC cells express IGF-I and IGFBP-3, and
are responsive to exogenous IGF-I stimulation. Moreover, in
SN12K1 cells (derived from metastatic RCC), autocrine IGF-
I and IGFBP-3 actions, respectively, stimulated and inhibited
growth. These results suggest that IGF-I and IGFBP-3 may be
potential candidates for therapeutic manipulation in patients
with advanced RCC.
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Renal cell carcinoma (RCC) accounts for 2% of all
malignancies. It is derived from the proximal tubular ep-
ithelium of the kidney and the major histologic subtype
is the clear cell/conventional RCC (about 75% of renal
neoplasms in all surgical series) [1]. Although surgery
is the standard treatment for localized disease [2], ap-
proximately one third of RCC patients present with
unresectable or metastastic disease for which current
systemic therapies are minimally effective [3, 4]. There-
fore, development of novel treatment alternatives is
imperative. Better understanding of the growth factor
pathways in RCC progression may aid in the advance-
ment of more effective therapeutic strategies.
Recent evidence suggests that members of the insulin-
like growth factor (IGF) family may play a key role
in RCC progression, and hence, may represent a po-
tential target for therapeutic manipulation [5, 6]. IGF-I
is a potent cell mitogen and antiapoptotic agent [5–7].
High serum IGF-I levels have been associated with an
increased risk of developing RCC [8], while high IGF-
I pretreatment levels in patients with established RCC
strongly predicted an impaired response to interleukin-
2 (IL-2) therapy. In experimental mice, injection of a
growth hormone-releasing hormone antagonist reduced
the IGF-I–induced proliferation of Caki-I RCC cell line
[9]. Furthermore, changes in the cellular transcription of
members of the IGF family have been observed in ferric
nitrilotriacetate-induced RCC in rats [10].
IGF-I exerts its biologic effects through binding to
IGF-I receptors (IGF-IR), and these effects can be mod-
ulated by one or more stimulatory or inhibitory IGF
binding proteins (IGFBPs). IGFBPs can, under certain
circumstances, potentiate the stimulatory effects of IGF-I
on cells by enhancing IGF-I presentation to its receptor
[11, 12], as well as by reducing the free ligand-accelerated
dissociation of IGF-I from IGF-IR [13]. Alternatively,
IGFBP-3 can also inhibit cell proliferation under certain
circumstances [14–16], either by sequestering IGF-I or
by IGF-I independent pathways, which include regula-
tion of downstream signaling pathways through specific
IGFBP-3 receptors and secondary messengers [16–19].
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Previous studies from our laboratory have shown that
IGF-I and IGFBP-3 mRNA and protein levels (but not
other IGFBPs) were up-regulated in human RCC (our
unpublished results), raising the possibility that these IGF
members may play a role in RCC development and/or
progression. The aim of the present study, therefore, was
to examine the expression of IGF-I and IGFBP-3, and the
effects of manipulating their actions in an in vitro model
of human RCC.
METHODS
Growth factors and antibody
IGF-I, mouse antihuman IGF-IR (clone 33255.111),
and a mouse IgG1 isotype control (clone 11711.11) were
purchased from R&D Systems (Bioscientific, Gymea,
Australia). Long R3-IGF-I, an IGF-I analog, which binds
to IGF-I receptor, but not to IGFBPs[20], was obtained
from Gropep (catalog number AU200; Gropep, Ade-
laide, Australia). Neutralizing antibodies assays against
human IGF-I (clone Sm1.2) and human IGF-IR (clone
33255.111), used in thymidine incorporation assays, were
purchased from Upstate Biotechnology (Lake Placid,
NY, USA) and R&D Systems, respectively. The human
anti-IGF-I antibody used for immunohistochemistry, was
a rabbit antibody from Gropep (catalog number PABCa).
The human recombinant IGFBP-3 was from Sigma-
Aldrich (Castle Hill, NSW, Australia). Neutralizing
rabbit antihuman IGFBP-3 antiserum was generously do-
nated by Professor Robert Baxter at the Kolling Insti-
tute of Medical Research in Sydney, Australia. This anti-
serum reacted with IGFBP-3 at a site other than the IGF-I
binding site [21]. Rabbit polyclonal antihuman IGFBP-3
antibody (clone H-98), obtained from Santa Cruz
Biotechnology (Santa Cruz, CA, USA), was used for
Western blotting and immunohistochemsitry.
Cells
Primary cultures of normal proximal tubular cell (PTC)
(priPTC) and RCC (priRCC) were isolated from patients
who underwent radical nephrectomy for localized clear
cell RCC. Informed consent was obtained from all pa-
tients involved. The collection and use of tissues were
approved by the Princess Alexandra Hospital Human
Research Ethics Committee. The priPTCs were estab-
lished from histologically normal segments of kidneys
remote from the tumor site. Cell isolations for nor-
mal PTCs were performed according to the method of
Johnson et al [22]. Briefly, tissues were decapsulated with
a pair of jeweler forceps, then chopped into small frag-
ments of about 1 cm3 using scalpels and razor blades
in a Petri dish (on ice). Fragments were washed three
times in 1:1 mixture of Ham’s F12 and Dulbecco’s mod-
ified Eagle’s media (DMEM/F12) (Trace Biosciences,
Melbourne, Australia), glucose concentration 17.5 mmol/
L, and digested with 1 mg/mL collagenase type II (Wor-
thington “Scimar;” Templestone, Victoria, Australia) for
20 to 30 minutes at 37◦C. Digested fragments were sieved
through an 80 to 100 lm mesh and the reaction was
halted by adding ice cold Krebs-Henseleit (KHS)-I solu-
tion (6.320 g/L NaCl, 0.363 g/L KCl, 0.389 g/L CaCl2.H2O,
0.430 g/L NaH2PO4, and 2.350 g/L NaHCO3). Cells were
washed twice with DMEM/F12 media before suspending
in 45% Percoll in KHS-II (KHS-II is a double strength so-
lution of KHS-I) and subjecting to high-speed centrifuga-
tion (20,000 rpm for 30 minutes). Tissues were separated
into four distinctive bands, F1 to F4. The lowermost band,
F4 (rich in PTCs), was carefully removed for cultures.
For RCC isolation, tumor tissue was processed as de-
scribed above, except that the “F1 layer,” where most
cells were enriched after Percoll separation, was col-
lected for cultures. The cells were washed twice with
DMEM/F12 and seeded in 75 cm3 tissue cultured flask
at 1 mg tissue/mL in appropriate tissue culture media.
Primary cells (priPTC and priRCCs) were checked for
appropriate markers (Cam 5.2 and vimentin) to confirm
their identities. Experiments were performed on second
or third passage primary cells (priPTC and priRCC) when
the growth rate of cells was most active and fibroblast
contamination was minimal (<0.5%).
Because priRCCs were nearly always obtained from
patients with localized disease, it was thought important
to also examine a cell line established from metastatic
RCC, namely SN12K1. The SN12K1 cell line was a gift
from Dr. Isaiah Fidler (Houston, TX, USA), and was ob-
tained from a lung metastasis in a patient with dissemi-
nated clear cell RCC.
Cell culture and experimental treatments for cell
proliferation studies
SN12K1 RCC cells and priRCCs were maintained in
10% fetal calf serum (FCS) in DMEM/F12. PriPTCs were
grown in “defined media” [(DMEM/F12 media supple-
mented with 5 lg/mL human apotransferrin (Sigma),
5 lg/mL bovine insulin (Sigma), 0.05 lmol/L hydrocor-
tisone (Sigma), 10 ng/mL mouse epidermal growth fac-
tor (Sigma), and 0.05 lmol/L synthetic prostaglandin E1
(Sigma)]. Cells were plated at a cell density of 4000
cells/cm2 (100 lL volumes) in 96-well culture plates. Sub-
confluent cells (70% confluent) were made quiescent by
incubation for 24 hours in “basic media” (DMEM/F12
media supplemented with transferrin). Quiescent cells
were then exposed to basic media containing growth fac-
tors and/or antibodies for a further 24 hours prior to
analysis.
Immunohistochemistry
Cells were grown on round 13 mm glass cover-
slips (Lomb Scientific, Taren Point, NSW, Australia) in
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24-well plates at a seeding density of 4000 cells/cm2. Qui-
escent cells were then cultured in basic media for 24 hours.
Media (1 mL) were collected, and centrifuged at 2000
rpm to remove cell debris. The supernatants were kept
for Western blotting analyses. Cells were fixed in 4%
paraformaldehyde in phosphate-buffered saline (PBS)
for 20 to 30 minutes and permeabilized with 0.2% Triton-
X-100 in Tris-buffered saline (TBS) at room temper-
ature. Endogenous peroxidases were removed by 3%
H2O2 in water and washed twice in TBS. Cells were
incubated with the Gropep rabbit antihuman IGF-I an-
tibody and Santa Cruz rabbit antihuman IGFBP-3 anti-
body in TBS for 30 minutes at 1/50 dilution (20 lg/mL
for IGF-I and 4 lg/mL for IGFBP-3) and were washed
twice with TBS with 3 minutes each. Secondary anti-
body incubation was performed with Envision Plus-HRP
(horseradish perioxidase) for rabbit antibody for 30 min-
utes (Dako, Botany, NSW, Australia). A brown chro-
mogenic signal was detected by diaminobenzidine plus
(DAB+) (Dako). Cells were then treated with Mayers
hematoxylin (Sigma), washed once with water, blued
with 0.25% sodium carbonate, dehydrated with graded
ethanol (from 70% to 100%), cleared with xylene, and
mounted in depex mounting media.
Thymidine incorporation
To ascertain the effect of IGF-I and IGFBP-3 on
priPTC, priRCC, and SN12K1 DNA synthesis, cells
were incubated in the presence of exogenous IGF-I,
IGFBP-3, and/or their antibodies for 24 hours in 96-well
tissue culture plates. Appropriate vehicle- and isotype
control antibody-treated cells were included for com-
parison. After 20 hours of incubation, 10 lL of diluted
3[H]-methyl-thymidine was added to the media to make
a final concentration of 4 lCi/mL. Media were removed
4 hours later at the end of the 24-hour incubation period.
Cells were gently washed once by PBS, followed by three
20-minute washes in 10% trichloroacetic acid (TCA).
They were then washed by methanol, air-dried, and re-
suspended in 100 lL of 0.3 mol/L NaOH/1% sodium do-
decyl sulfate (SDS). Fifty microliters of the suspensions
were mixed thoroughly with 1 mL of scintillant (Packard,
Melbourne, Australia). The radioactivity in samples was
counted in a b-scintillation counter.
3–4,5 dimethylthiazol-2,5 diphenyl tetrazolium bromide
(MTT) assays
DNA synthesis results were verified by 3–4,5
dimethylthiazol-2,5 diphenyl tetrazolium bromide
(MTT) assays, which were performed according to the
methods of Denizot and Lang [23] and Twentyman
and Luscombe [24]. Following treatment in each of the
experimental groups, media were removed from cells
and 50 lL of 0.5 mg/mL MTT, prepared with phenol-red
free DMEM/F12 media, were added to the wells in
96-well culture plates. The plates were incubated at
37◦C for 15 minutes. MTT solutions were removed and
100 lL of dimethyl sulfoxide (DMSO) were added.
The plates were agitated for 5 minutes to fully dissolve
crystals. Absorbance was measured at 540 nm, and
background was subtracted at 690 nm by Labsystems
iEMS Reader MF spectrophotometric plate reader and
Ascent software, version 2.4.1 (Labsystems, Helsinki,
Finland).
Western blotting
Western blotting was performed on media conditioned
by priPTC, priRCC, and SN12K1 cells incubated in the
presence or absence of IGF-I or vehicle for 24 hours. Prior
to Western blotting, protein assays were performed on
the conditioned media to ascertain similar protein lev-
els would be loaded. The “microassay” procedure for
the Bio-Rad Protein Assay protocol (Bio-Rad, Hercules,
CA, USA) was carried out according to the manufac-
turer’s instructions. For Western blotting, samples were
separated under reducing conditions on a Novex 4% to
12% Bis-Tris gel (Invitrogen, Melbourne, Australia) for
1 hour at 200 V using 3-[N-morpholino] propane sulfonic
acid (MOPS) buffer. Proteins were then transferred onto
polyvinylidine difluoride (PVDF) membranes using a
semidry blotting method according to the manufacturer’s
instructions. For immunoblotting, membranes were wet-
ted with methanol briefly and rinsed in TBS/0.1% Tween.
They were then blotted overnight at 4◦C with 5% skim
milk powder in TBS/0.1% Tween and washed twice with
TBS/0.1% Tween. For incubation of primary antibody,
rabbit antihuman IGFBP-3 antibody was incubated at
1:400 dilution in TBS/0.1% Tween. Washes were per-
formed in TBS/0.1% Tween. Secondary antibody incu-
bations were performed at 1:3000 in TBS/0.1% Tween.
Membranes were incubated in the enhanced chemilu-
minescence (ECL Plus Substrate; Amersham Pharma-
cia, Castle Hill, NSW, Australia), and then exposed to
Hyperfilm-enhanced autoradiographic film (Amersham
Pharmacia).
Statistical analysis
Results were expressed as mean ± SD. All studies
involving priPTC and priRCC were performed in six
replicates from at least four different human donors. Ex-
periments involving SN12K1 cells were performed in six
replicates on at least two separate occasions. Each ex-
periment contained internal controls originating from
the same culture preparation. For the purpose of anal-
ysis, each experimental result was expressed as a change
from the control value, which was regarded as 100%,
and analyzed independently. Statistical comparisons be-
tween groups were made by one-way analysis of vari-
ance (ANOVA). Pair-wise multiple comparisons for sig-
nificant ANOVA results were made by Fisher protected
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Fig. 1. Representative results of insulin-like growth factor-I (IGF-I) and IGF binding protein 3 (IGFBP-3) immunostainings on primary proximal
tubular cells (priPTC), primary renal cell carcinoma (priRCC), and SN12K1 RCC. Positive stainings appeared as brown discoloration (magnifications
were 200×). IGF-I and IGFBP-3 were strongly expressed in SN12K1 RCC cell lines and weakly expressed in priPTC and priRCC. IGF-I staining
in (A) SN12K1, (B) priPTC,and (C) priRCC. IGFBP-3 staining in (D) SN12K1, (E) priPTC, and (F) priRCC. Negative isotype antibody controls
for (G) SN12K1, (H) priPTC, and (I) priRCC. Arrows indicate cytoplasmic stainings (Ct), whereas arrowheads represent nuclear stainings (N).
least-significant differences test. Analyses were per-
formed using the software package SPSS version 11.0
(North Ryde, Australia). P values less than 0.05 were con-
sidered significant.
RESULTS
IGF-I and IGFBP-3 were strongly expressed in SN12K1
but weakly expressed in priPTCs and priRCC
Immunohistochemical staining of SN12K1 cells
showed appreciable expression of IGF-I (Fig. 1A) and
IGFBP-3 (Fig. 1D). Cell-associated IGFBP-3 and IGF-I
immunostainings were mainly localized in the cytoplasm
and occasionally in nuclei. In contrast, IGF-I and IGFBP-
3 were only weakly expressed in priPTC (Fig. 1B and E)
and priRCC (Fig. 1C and F).
IGF-I stimulates DNA synthesis in priPTC, priRCC, and
SN12K1 RCC
IGF-I at 100 ng/mL significantly stimulated thymidine
incorporation by priPTCs (120.7% ± 19.7% of control
values, P < 0.05), priRCCs (238.7% ± 279.9% of control
values, P < 0.01), and SN12K1 cells (120.0% ± 22.9% of
control values, P < 0.05) (Fig. 2). The magnitude of IGF-
I–induced DNA synthesis compared to vehicle-treated
controls was significantly greater in priRCC cells com-
pared to priPTCs and SN12K1 RCC cells.
MTT assays were performed to verify the results of
the thymidine incorporation experiments. SN12K1 cell
growth was significantly stimulated when incubated with
IGF-I for 24 hours, as shown by MTT assay (116.7% ±
4.0% of vehicle control, P < 0.01). This result was sup-
portive of the DNA synthesis data for SN12K1. The assay
was not performed on priPTC and priRCC due to the rel-
atively limited supply of primary cell stocks.
IGF-I immunoneutralization suppresses SN12K1
and priPTC growth but not priRCC growth
SN12K1 cells, which exhibited positive immunohisto-
chemical staining for IGF-I, exhibited significant suppres-
sion of thymidine incorporation in the presence of 10
lg/mL anti-IGF-I (81.9% ± 13.5% of controls, P < 0.01)
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Fig. 2. Thymidine incorporation of insulin-like growth factor-I (IGF-
I) treatment in normal proximal tubular cells (PTCs) (N = 21), renal
cell carcinomas (RCCs) (N = 30), and SN12K1 RCC (N = 18) cell
line cultures. Results were normalized against their own internal ve-
hicle controls and expressed as % of control (mean ± SD). Control
values (100%) were depicted by the dotted line. The average thymidine
incorporation values of IGF-I vs. vehicle treatment (dpm/culture well)
before correcting against vehicle controls were 8059 ± 1716 vs. 6600 ±
2000 primary PTC (priPTC); 2063 ± 1891 vs. 1103 ± 792 primary RCC
(priRCC); and 194515 ± 93368 vs. 160485 ± 54267 SN12K1. ∗P < 0.05
vs. control; ∗∗P < 0.01 vs. control and other groups.
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Fig. 3. Thymidine incorporation of insulin-like growth factor-I (IGF-I)
axis intervention. The effect of blocking autocrine IGF-I was examined
by incubation of primary proximal tubular cells (priPTC) (N = 24),
primary renal cell carcinoma (priRCC) (N = 24), and SN12K1 RCC
(N = 12) with anti-IGF-I or anti-IGF-I receptor (IGF-IR) alone. The
dotted line represented control values observed in isotype antibody-
treated cells. Results were expressed as % of control (mean ± SD).
∗P < 0.05; ∗∗P < 0.01 vs. isotype antibody control-treated cells.
(Fig. 3) or 10 lg/mL anti-IGF-IR (87.4% ± 16.2% of con-
trols, P < 0.05).
Similarly, anti-IGF-I but not anti-IGF-IR significantly
suppressed thymidine incorporation by priPTC (89.7% ±
8.3%, P < 0.05; and 93.4% ± 18.2% of controls, P = NS).
However, no significant effects were observed in priRCC
treated with the same antibodies(105.0% ± 27.9% and
105 ± 35.3% of controls, P = NS).
IGFBP-3 expression in SN12K1 RCC cells
is stimulated by IGF-I
To determine the effect of IGF-I on endogenous pro-
duction of IGFBP-3, IGFBP-3 protein expression was
priPTC priRCC SN12K1
IGF-I Vehicle IGF-I Vehicle IGF-I Vehicle
38-41 kD
IGFBP-3
Fig. 4. The effect of insulin-like growth factor-I (IGF-I) treatment on
IGF binding protein 3 (IGFBP-3) protein expression. Western blot of
media conditioned by primary proximal tubular cells (priPTC), primary
renal cell carcinoma (priRCC), and SN12K1 cell incubated in the pres-
ence of 100 ng/mL IGF-I or vehicle for 24 hours. IGFBP-3 appeared
between 38 to 41 kD at reducing conditions of sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) protein electrophore-
sis. A representative sample and its vehicle-treated control from each
cell type were shown. Western analysis was performed in duplicate sets
and both sets showed similar results.
examined in IGF-I–treated priPTC, priRCC, or SN12K1
cells by Western blotting. As determined by protein as-
says, no significant difference in total protein secretion
was present between IGF-I–treated and vehicle-treated
cells for all cell types. Protein levels between IGF-I–
treated and vehicle-treated groups were 1.7 ± 0.9 lg/mL
and 2.0 ± 0.03 lg/mL (priPTC, P = NS); 6.3 ± 0.7 lg/mL
and 6.0 ± 0.5 lg/mL (priRCC, P = NS); and 10.7 ±
7.2 lg/mL and 12.1 ± 8.5 lg/mL (SN12K1, P = NS). Com-
pared with vehicle-treated controls, secreted IGFBP3
levels were up-regulated 10.7-fold of control follow-
ing 24-hour exposure to 100 ng/mL IGF-I (Fig. 4) for
SN12K1 cells. IGFBP-3 in the conditioned media existed
as 38 to 41 kD doublets under reducing electrophoresis
conditions. There was no detectable secreted IGFBP-3
for priPTC and priRCC under the same experimental
conditions.
IGFBP-3 inhibits the growth of SN12K1, but not
priPTC or priRCC
As IGFBP-3 might play a part in regulating DNA syn-
thesis via IGF-I–dependent or IGF-I–independent ef-
fects, we tested this possibility by treating SN12K1 RCC,
priPTC, and priRCC with exogenous IGFBP-3 in the
presence or absence of a specific neutralizing antibody
against IGFBP-3 (Fig. 5). The amount of exogenous
IGFBP-3 (300 ng/mL) used was based on previous data
that primary cultures of cortical fibroblast surrounding
priPTC produced around 266 ± 38 ng/mL/day of IGFBP-
3 [25]. The anti-IGFBP-3 antisera concentration used in
this experiment (1:500 dilution) was previously found to
neutralize 200 ng/mL of IGFBP-3.
Adding 300 ng/mL exogenous IGFBP-3 did not in-
fluence SN12K1 DNA synthesis (Fig. 5). However,
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Fig. 5. DNA synthesis on SN12K1 renal cell carcinoma (RCC) cell
line, primary proximal tubular cells (priPTC), and primary renal cell
carcinoma (priRCC) with manipulation of insulin-like growth factor
binding protein 3 (IGFBP-3). SN12K1 cells (N = 6), priPTC (N = 42),
and priRCC (N = 35) were incubated for 24 hours in the presence or
absence of 300 ng/mL recombinant human IGFBP-3 (h-IGFBP-3) with
and without neutralizing anti-IGFBP-3 antibody (1:500). Results were
corrected against their own internal controls (vehicles) and expressed
as % of control (mean ± SD). The dotted line depicts the control values
(100%). ∗P < 0.001 vs. control; #P < 0.001 vs. anti-IGFBP-3.
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Fig. 6. Effect of insulin-like growth factor binding protein 3 (IGFBP-3)
immunoneutralization on IGF-I- and Long R3-IGF-I–induced SN12K1
DNA synthesis (N = 6). Thymidine incorporation was measured in
SN12K1 cells exposed for 24 hours to 100 ng/mL IGF-I or Long R3-
IGF-I in the presence or absence of anti-IGFBP-3. Both results were
corrected against their own vehicle-treated internal controls and were
presented as mean ± SD. ∗∗∗P < 0.001 vs. the absence of anti-IGFBP3 in
IGF-I–treated or Long R3-IGF-I–treated cells; ###P < 0.001 vs. IGF-I
+ anti-IGFBP-3.
immunoneutralization of endogenous IGFBP-3 with
1:500 dilution of anti-IGFBP-3 significantly stimulated
thymidine incorporation (243.9% ± 35.5% of control,
P < 0.001). These stimulatory effects were partially abro-
gated by coincubation of cells with 300 ng/mL of exoge-
nous IGFBP-3 (135.97% ± 5.9% of control, P < 0.001).
Since previous experiments demonstrated that IGF-I in-
duced endogenous IGFBP-3 production by SN12K1, the
possibility that IGF-I–induced DNA synthesis was mod-
ulated by altered autocrine IGFBP-3 action was further
assessed by IGFBP-3 immunoneutralization. In Figure 6,
IGF-I–induced DNA synthesis was further augmented by
coincubation with neutralizing anti-IGFBP-3 antibody.
Very similar effects were observed in cells treated with
100 ng/mL Long R3-IGF-I (an IGF-I analog which binds
to and stimulates the IGF-I receptor but does not bind to
IGFBPs).
In contrast to SN12K1 cells, neither priPTC nor
priRCC exhibited significant changes in DNA synthesis
following incubation with IGFBP-3 and/or anti-IGFBP-3
(Fig. 5).
In keeping with the DNA synthesis data, coincuba-
tion of anti-IGFBP3 with 100 ng/mL IGF-I or with
100 ng/mL Long R3-IGF-I significantly increased cell
growth as determined by the MTT assay (IGF-I + anti-
IGFBP-3: 112.7% ± 1.9% of IGF-I alone control, P <
0.01; and Long R3-IGF-I + anti-IGFBP-3: 126.9 ± 1.0%
of Long R3-IGF-I alone control; P < 0.01, respectively).
DISCUSSION
In this paper, the effects of IGF-I and IGFBP-3 were
evaluated in priPTCs, priRCC, and a metastatic RCC cell
line (SN12K1). IGF-I and IGFBP-3 were strongly ex-
pressed by SN12K1, but weakly expressed in both priPTC
and priRCC. Exogenous IGF-I induced cell growth in all
cell types. Furthermore, endogenous IGFBP-3 produc-
tion in SN12K1 cells was stimulated by IGF-I and re-
sulted in autocrine suppression of RCC growth. Taken
together, these results suggest that IGF-I and IGFBP-3
may play important roles, respectively, in stimulating and
regulating growth, particularly in its advanced stages.
The present study supports and extends the findings of
previous in vitro and in vivo studies, which have shown
that IGF-I is a potent mitogen for RCC [5, 9]. IGF-
I was found to play an important role in renal cellu-
lar transformation induced by proto-oncogenes (such as
c-myb) and viral DNA oncogenes (such as SV40 T-
antigen) [26]. Moreover, alterations in the cellular tran-
scription of IGF/IGFBP family members have been
found to precede the development of RCC in rats treated
with ferric nitrilotriacetate [10]. The risk of RCC is also
substantially increased in obese individuals [8], and it has
been speculated that this may be related to the higher
serum levels of IGF-I observed in overweight patients.
Biallelic von Hippel-Lindau (VHL) mutations, which oc-
cur in more than 70% of sporadic clear cell RCCs, have
also recently been shown to enhance RCC growth and in-
vasiveness by augmenting IGF-I signaling [5]. Blocking
IGF-I or IGF-IR signaling abolished or delayed the pro-
gression of a variety of tumors in animal models [27], and
Lissoni et al [28] have demonstrated that high pretreat-
ment serum levels of IGF-I in patients with clear cell RCC
are associated with a substantially impaired response to
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IL-2 immunotherapy. A subcutaneously injected growth
hormone releasing hormone (GH-RH) antagonist,
MZ-4–71, has been shown to inhibit the IGF-I–induced
proliferation of the Caki-I RCC cell line in mice [9].
All cell types tested in the present study showed re-
sponsiveness to exogenous IGF-I stimulation, as indi-
cated by significant increases in DNA synthesis. The
IGF-I–induced DNA synthesis in SN12K1 cells was IGF-
I–specific and IGF-IR–mediated since it was completely
abrogated by both anti-IGF-I and anti-IGF-IR anti-
bodies. Endogenous IGF-I expression, as evidenced by
immunohistochemical staining, was more pronounced
in SN12K1 cells than priRCC. Moreover, IGF-I im-
munoneutralization suppressed growth of SN12K1 but
not priRCC. This suggests that autocrine IGF-I action
plays a significant role in SN12K1 growth stimulation,
but not in priRCC. The disparity in results between these
two cells may relate to the transformation of SN12K1
cells, or alternatively, may be due to their difference in
tumor stage since priRCCs were developed from patients
with localized disease and SN12K1 cells were established
from metastatic RCC.
IGFBP-3, which exerts both IGF-I–dependent and
IGF-I–independent actions, has also been implicated in
RCC development. Recent studies using cDNA microar-
ray, suppression subtractive hybridization and Northern
blot analyses have identified IGFBP-3 as one of the com-
monly up-regulated genes in pathologic samples of clear
cell RCC and established RCC cell lines [29, 30]. The
functional consequences IGFBP-3 in normal cell sys-
tems and malignancies are complex and could poten-
tially involve both stimulatory and inhibitory effects [6,
20, 31, 32]. In the present study, IGFBP-3 was clearly
up-regulated in SN12K1 cells and appeared to act in an
autocrine action to suppress cell growth.
The significance of IGFBP-3 in the regulation of RCC
progression is not well understood, but we hypothesized
that its up-regulation may have represented a compen-
satory inhibitory mechanism in response to unrestrained
IGF-I–induced cell growth. In SN12K1 cells, IGF-I stimu-
lated DNA synthesis concurrently with IGFBP-3 produc-
tion (Figs. 2 and 4). Similar studies by Grill and Cohick
[33] have also shown that IGF-I–induced production of
IGFBP-3 in an immortalized bovine mammary epithelial
cell line maintained a regulatory growth loop. The authors
claimed that an increase in IGFBP-3 enhanced cellular
responsiveness to IGF-I, as reflected by “mock cells” (de-
void of IGFBP-3) having less intense IGF-I–stimulated
cell growth than IGFBP-3–expressing cells. While we ob-
served similar increases in DNA synthesis and IGFBP-
3 production with IGF-I incubation (Figs. 2 and 4), the
IGF-I–enhanced DNA synthesis was accentuated when
IGFBP-3 was removed (Fig. 6). To further evaluate if this
effect was dependent upon extracellular sequestration of
IGF-I, Long R3-IGF-I, an analog of IGF-I, was coincu-
bated with neutralizing IGFBP-3 antibody. IGFBP-3 im-
munoneutralization significantly augmented the stimula-
tory effects of both IGF-I and Long R3-IGF-I on SN12K1
cells DNA synthesis, suggesting that the inhibitory au-
tocrine effects of IGFBP-3 were predominantly mediated
by IGF-I–independent mechanisms. Nevertheless, Long
R3-IGF-I exerted a marginally greater mitogenic effect
than an equipotent dose of IGF-I, indicating that a small
component of the antiproliferative effects of IGFBP-3
may have involved extracellular sequestration of IGF-I.
Nevertheless, it is difficult to determine whether the
IGFBP-3 effects demonstrated in this paper were solely
IGF-I–dependent or IGF-I–independent (or a combina-
tion of both) as SN12K1 cells do express IGF-I, which
may interfere with IGFBP-3. The classical theories of
IGF-I–dependent effects proposed for IGFBP-3 include
potentiation of IGF-I action by IGFBP-3 [11, 12] and in-
hibition of IGF-I action by sequestration of extracellular
peptides [20]. In addition, IGFBP-3 has been reported to
exert a number of IGF-I–independent effects, including
the inhibition of IGF-IR autophosphorylation and tyro-
sine kinase activity [34], signaling via cell surface type
V transforming growth factor-b (TGF-b) receptors for
IGFBP-3 [14, 35], mitogen-activated protein (MAPK) ac-
tivation [36], up-regulation of kinase phosphatases [17],
activation of growth inhibitory TGF-b , and Smad path-
ways [18, 19].
In the present study, IGF-I and IGFBP-3 immunore-
activity were present in the cytoplasm and nuclei, a find-
ing that is similar to that in lung cancer [37, 38]. The
significance of this in RCC is uncertain. However, nu-
clear transport studies by Li et al [39] indicate that two
signaling pathways may be possible. First, cotransporta-
tion of IGF-I and IGFBP-3 complex across the plasma
membrane could lead to nuclear accumulation of the pep-
tides, resulting in direct nuclear transcription of factors
involved in cell growth. Alternatively, IGF-I and IGFBP-
3 could be internalized into the endosomal compartments
via receptor-mediated pathways, where their subsequent
action may be mediated by cytoplasmic secondary mes-
senger systems.
CONCLUSION
IGF-I and IGFBP-3 were most highly expressed in
SN12K1 cells, a cell line developed from RCC metas-
tasis. In these cells, IGF-I acted in an autocrine fashion
to stimulate the growth of renal cell carcinomas and their
secretion of IGFBP-3. IGFBP-3 in turn served to recipro-
cally inhibit cellular growth, acting as a brake for endoge-
nous IGF-I action. Further investigation of the potential
therapeutic value of inhibiting IGF-I and/or promoting
IGFBP-3 action in animal RCC models is warranted.
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